Latest Breaking News On - ஜாஸ் மருந்து - Page 4 : comparemela.com

Share this article Share this article DUBLIN, June 30, 2021 /PRNewswire/  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze ™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in pediatric and adult patients one month and older who have developed hypersensitivity to E. coli-derived asparaginase. 1  Rylaze is the only recombinant erwinia asparaginase manufactured product that maintains a clinically meaningful level of asparaginase activity throughout the entire duration of treatment, and it was developed by Jazz to address the needs of patients and healthcare providers with an innovative, high-quality erwinia-derived asparaginase with reliable supply.  

United statesNew zealandJacqueline kirbyAndrean flynnLuke maeseJazz pharmaceuticals incCommission file noNational cancer instituteOncology centerJazz pharmaceuticalsUniversity of utahLeukemia foundationAmerican cancer societyNational clinical trials networkChildren oncology groupHuntsman cancer institute